 |
 |
Isn't that what Eldepryl was also supposed to do? I feel like a Pawn.... Nic 56,14 On Mon, Jun 16, 2008 at 8:21 PM, rayilynlee <[log in to unmask]> wrote: > Teva, Lundbeck say Azilect slows Parkinson's > > Reuters - 41 minutes ago > TEL AVIV/STOCKHOLM, June 16 - Teva Pharmaceutical Industries Ltd revealed > positive results on Monday for its Azilect Parkinson's treatment, boosting > its shares and those of Danish partner Lundbeck . > Tel Aviv-traded shares in Teva jumped 3.2 percent while Lundbeck was up 3.7 > percent at 1336 GMT. > Teva, the world's biggest maker of generic drugs, said it intends to submit > these results to the regulatory authorities in the United States and Europe. > It said the 1 mg tablets of its Azilect drug slowed the progression of > Parkinson's disease in a Phase III trial. It promotes the drug with Lundbeck > in the three major European markets: Britain, Germany and France. > Teva and Lundbeck said 1 mg tablets of Azilect met all three primary end > points in the trial, as well as the secondary and additional end points, all > with statistical significance. > The study also confirmed the safety and tolerability of Azilect and based > on these results, Azilect could become the first Parkinson's disease > treatment to receive an indication for slowing the progress of the disease, > the companies said. > "These positive results could dramatically increase the market potential > for Azilect, allowing Azilect to join Copaxone as another major Teva drug > for neurological disorders," Shlomo Yanai, president and chief executive of > Teva, said in a statement. > Teva's Copaxone became the No. 1 global treatment for multiple sclerosis in > the first quarter. > "Azilect, an innovative drug that was not very significant, becomes a drug > with the potential to be a blockbuster," said Gal Reiter, an analyst at > Israeli brokerage Clal Finance. > SALES TO JUMP > Global sales of Azilect rose 50 percent in the first quarter from a year > earlier to $37.5 million. It sales were $120 million in 2007. > "If in the past we estimated the potential sales of the drug at $300 > million, now we estimate that the potential has at least doubled," Reiter > said. > "However, it will take time until Azilect's impact becomes substantial." > The analyst noted that while Azilect's patent runs until 2012, this > clinical trial could enable an extension until 2017. > Bank Hapoalim analyst Gilad Sarig estimated Azilect's potential sales at $1 > billion. > "It is expected to become the leading drug in the Parkinson's market within > a few years," he said in a research note, adding he is not changing his > forecasts for the company until the timetable with the FDA becomes clear. > The study protocol was based on the recommendations and guidance of the > U.S. Food and Drug Administration. The 18-month study, the first of its > kind, is one of the largest conducted in Parkinson's disease, involving > 1,176 patients with early Parkinson's disease in 14 countries and 129 > medical centres. > Teva also said the 2 mg dose in the study met two of the three primary end > points as well as the secondary end point. It was also found to be safe and > well tolerated. > Rayilyn Brown > Director AZNPF > Arizona Chapter National Parkinson Foundation > [log in to unmask] > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto: > [log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn